Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Packer

Showing results (161-170 of 4,797) with videos related to

Pageof 480
Sort By:
European Heart Journal|April 1, 1996
Beta-blockade in the management of chronic heart failure. Another step in the conceptual evolution of a neurohormonal model of the diseaseM Packer
The American Journal of Cardiology|March 25, 1993
How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the diseaseM Packer
Journal of Internal Medicine|April 1, 1996
New concepts in the pathophysiology of heart failure: beneficial and deleterious interaction of endogenous haemodynamic and neurohormonal mechanismsM Packer
Journal of the American College of Cardiology|November 1, 1996
Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?M Packer
The Israel Journal of Psychiatry and Related Sciences|November 6, 1998
Jewish mystical movements and the European ergot epidemicsS Packer
The American Journal of Cardiology|January 3, 1989
Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failureM Packer
The New England Journal of Medicine|December 12, 2019
Why Are Physicians So Confused about Acute Heart Failure?. ReplyMilton Packer
Diabetes, Obesity & Metabolism|January 10, 2020
Interplay of adenosine monophosphate-activated protein kinase/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual frameworkMilton Packer
Diabetes Research and Clinical Practice|January 20, 2020
Concerns about the use of metformin as a first-line agent to slow the progression of chronic kidney disease in diabetesMilton Packer
European Journal of Heart Failure|October 31, 2017
Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure?Milton Packer
Pageof 480

Showing results (161-170 of 4,797) with videos related to

Sort By:
Pageof 480
European Heart Journal|April 1, 1996
Beta-blockade in the management of chronic heart failure. Another step in the conceptual evolution of a neurohormonal model of the diseaseM Packer
The American Journal of Cardiology|March 25, 1993
How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the diseaseM Packer
Journal of Internal Medicine|April 1, 1996
New concepts in the pathophysiology of heart failure: beneficial and deleterious interaction of endogenous haemodynamic and neurohormonal mechanismsM Packer
Journal of the American College of Cardiology|November 1, 1996
Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?M Packer
The Israel Journal of Psychiatry and Related Sciences|November 6, 1998
Jewish mystical movements and the European ergot epidemicsS Packer
The American Journal of Cardiology|January 3, 1989
Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failureM Packer
The New England Journal of Medicine|December 12, 2019
Why Are Physicians So Confused about Acute Heart Failure?. ReplyMilton Packer
Diabetes, Obesity & Metabolism|January 10, 2020
Interplay of adenosine monophosphate-activated protein kinase/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual frameworkMilton Packer
Diabetes Research and Clinical Practice|January 20, 2020
Concerns about the use of metformin as a first-line agent to slow the progression of chronic kidney disease in diabetesMilton Packer
European Journal of Heart Failure|October 31, 2017
Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure?Milton Packer
Pageof 480